OncRef

Clinical Trial: NCT02981628

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:Children's Oncology Group
Information Provided By:Children's Oncology Group
Last Update Posted:2026-10-01

Study Overview

Brief Summary

This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.

Official Title

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Conditions

Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma

Intervention / Treatment

  • Drug: Asparaginase Erwinia chrysanthemi
  • Procedure: Biospecimen Collection
  • Procedure: Bone Marrow Aspiration and Biopsy
  • Drug: Calaspargase Pegol
  • Drug: Cyclophosphamide
  • Drug: Cytarabine
  • Procedure: Diagnostic Imaging Testing
  • Biological: Inotuzumab Ozogamicin
  • Drug: Leucovorin Calcium
  • Procedure: Lumbar Puncture
  • Drug: Methotrexate
  • Drug: Pegaspargase
  • Drug: Vincristine

Other Study ID Numbers

  • AALL1621
  • NCI-2016-01494
  • AALL1621
  • AALL1621
  • U10CA180886

Start Date (Actual)

2017-06-19

Primary Completion Date (Estimated)

2026-12-31

Study Completion Date (Estimated)

2026-12-31

Enrollment (Estimated)

80

Study Type

Interventional

Phase

Phase 2